Contact Us
Home
Who We Are
Our Services
Value Proposition
Territories
News
Contact Us

Principals

Peter Zaudtke, Solem Principal

Peter Zaudtke photo   Several years experience in Oncology, Infectious Disease, Vaccines
  • Founded and built US HQ and EU subsidiary as CFO and VP of Operations for small oncology biotech. Responsible for all of the day to day company operations of both companies including acquisition and transition of oncology product from Schering Plough.
  • Led transition of medical device product onto customized pan European supply chain developed for Solem client
  • Led Ex-US commercial infrastructure plans for MedImmune’s seasonal flu vaccine
  • Responsible for commercial management of MedImmune’s $500M ex-US ID franchise


Dr. Gabi Kothny-Wilkes, Solem Principal

Dr. Gabi Kothny-Wilkes photo   Several years of experience in Oncology (hematological, solid), Rheumatology, Dermatology, Transplantation and Medical Devices

  • Directed the design and establishment of a global sales and marketing division as Global Head of Sales, Marketing and BD for Suwelack Skin & Healthcare
  • Prepared the global launch plan for the Oncology business in Wyeth with a focus on EMEA including full commercial infrastructure as European Commercial Director Oncology
  • Global Launch of Torisel® (kidney cancer)
  • Mylotarg® (orphan drug status for AML)
  • Pipeline Products
  • Management of German Enbrel® biopharma business (Wyeth) including pre-marketing activities, marketing strategies and successful launch of new indications and devices


Jürgen Reiher, Solem Principal

Dr. Gabi Kothny-Wilkes photo    Several years of experience in Hemophilia, Oncology, Rheumatology, Vaccines, Infectious Disease, Gynecology and Dermatology

  • Developed and authored integrated, multifunctional, event based, strategic marketing and launch plan for Wyeth currently leveraged by Solem today
  • Led implementation of strategic marketing and launch planning in 7 therapeutic areas
  • Launched Prevnar®, Meningitec®, initial preparations for nasal flu vaccine (CAIV-T)
  • 5 years bench research in neuroendocrinology